Browse News
Filter News
Found 9 articles
-
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
3/6/2024
Vaxart, Inc. announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024.
-
Valitor Expands Leadership Team with Appointment of Omkar Joshi, Ph.D. as Vice President of CMC
7/19/2023
Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced the appointment of Omkar Joshi, Ph.D., as vice president of CMC.
-
Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Vision and Ophthalmology Annual Meeting
4/24/2023
Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced new data from VLTR-557, its long-acting anti-VEGF biologic in development for durable wet age-related macular degeneration (AMD) treatment
-
Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting
4/10/2023
Valitor today announced that data reviewing the therapeutic potential of its Multivalent Polymer (MVP) technology in oncology has been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.
-
Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
3/23/2023
Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that two abstracts have been accepted for poster presentation at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting taking place April 23-27, 2023 in New Orleans, LA.
-
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
3/21/2023
DURECT Corporation announced that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.
-
Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit - Preclinical data support twice-yearly dosing in wet AMD -
12/1/2022
Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that its president and chief scientific officer, Wesley Jackson, Ph.D., will present at the Ophthalmology Innovation Source XII Summit in San Diego, CA on December 3, 2022.
-
Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer
10/5/2022
Valitor, a biotechnology company engineering better medicines to conquer drug limitations, announced that it has closed a Series B financing and named Steven Lo as chief executive officer and member of the board.
-
DURECT Corporation Appoints Two New Board Members
1/5/2021
DURECT Corporation announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.